•A U.S. National Intelligence Council assessment concluded that military intervention, whether through airstrikes or a prolonged war, was unlikely to result in regime change in Iran.
•The assessment was completed in February 2026, shortly before military operations were launched by the United States and Israel.
•ImmunityBio announced the resubmission of a supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG for the treatment of papillary NMIBC.
•The FDA acknowledged receipt of the filing following a review of additional data provided by the company in February 2026.
•The treatment targets approximately 70% of NMIBC patients who present with papillary disease.
•Starboard Value LP, a significant stockholder in Lamb Weston Holdings Inc. (LW), announced it has delivered a letter to the Company's CEO and Board of Directors.
•Starboard Value is a well-known activist investor that typically seeks strategic or operational changes in its portfolio companies.
•The American Society of Breast Surgeons (ASBrS) updated its 2026 Resource Guide to recommend cryoablation as an option for low-risk early-stage breast cancer patients.
•The recommendation is based on IceCure's ICE3 study results and a favorable FDA Advisory Panel vote.
•The update is expected to accelerate commercial adoption of IceCure Medical's ProSense technology following FDA clearance.
•Relmada Therapeutics (RLMD) announced an oversubscribed $160.0 million private investment in public equity (PIPE) financing.
•Relmada's financing included participation from major institutions like Venrock Healthcare Capital Partners, Janus Henderson Investors, and RA Capital Management.
•PyroGenesis (PYR) announced its intention to complete a non-brokered private placement to raise up to $1,000,000 at $0.54 per unit.
•The US Department of Transportation and FAA selected Archer's partners in Texas, Florida, and New York to participate in the eVTOL Integration Pilot Program (eIPP).
•The program marks a major step toward commercializing electric air taxis in the US, representing the first new aircraft category in nearly 80 years.
•Telix Pharmaceuticals announced that Part 1 of the ProstACT Global Phase 3 study for its therapeutic candidate TLX591-Tx has achieved its primary objectives.
•The study demonstrated an acceptable safety and tolerability profile with no new safety signals observed in the safety and dosimetry lead-in phase.